Endothelium

Turn Biotechnologies' Expanded eTurna™ Delivery Platform Designed to Solve Delivery and Targeting Issues that Challenge Industry

Retrieved on: 
Wednesday, January 3, 2024
Particle size, Messenger, Fibroblast, PEG, Tissue, Macrophage, Ionization, Keratinocyte, Lipid, Blood, Endothelium, Transfection, Cell, Safety, Medicine, Skin, Vaccine

The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.

Key Points: 
  • The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.
  • Since the platform can utilize PEG-free stabilizing components, the delivery system minimizes or eliminates immunogenicity associated with PEG lipids currently used in LNPs.
  • "It is designed to enable the delivery of therapies to treat incurable diseases by targeting cells that medicine cannot currently reach.
  • Turn Bio's first drug candidates are focused on treating the skin by targeting specific cells including fibroblasts, endothelial cells and keratinocytes.

Turn Biotechnologies' Expands eTurna™ Delivery Platform to Solve Delivery and Targeting Issues that Challenge Industry

Retrieved on: 
Wednesday, January 3, 2024
Particle size, Messenger, Fibroblast, PEG, Tissue, Macrophage, Ionization, Keratinocyte, Lipid, Blood, Endothelium, Transfection, Cell, Safety, Medicine, Skin, Vaccine

The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.

Key Points: 
  • The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.
  • Since the platform can utilize PEG-free stabilizing components, the delivery system minimizes or eliminates immunogenicity associated with PEG lipids currently used in LNPs.
  • "It is designed to enable the delivery of therapies to treat incurable diseases by targeting cells that medicine cannot currently reach.
  • Turn Bio's first drug candidates are focused on treating the skin by targeting specific cells including fibroblasts, endothelial cells and keratinocytes.

Vascular Perfusion Solutions and Unravel Biosciences announce partnership to modulate endothelial activation during heart preservation to improve heart transplant outcomes

Retrieved on: 
Monday, November 27, 2023
Ischemia, Science, Partnership, Survival, Risk, Research, VPS, Health, Organ transplantation, Endothelium, Transplant, Patient, Vaccine

BOSTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vascular Perfusion Solutions (VPS) and Unravel Biosciences, Inc. (“Unravel”) are partnering to develop a proprietary perfusion solution that will enhance organ viability during transport and reduce the risk of acute rejection following transplantation.

Key Points: 
  • BOSTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vascular Perfusion Solutions (VPS) and Unravel Biosciences, Inc. (“Unravel”) are partnering to develop a proprietary perfusion solution that will enhance organ viability during transport and reduce the risk of acute rejection following transplantation.
  • The partnership utilizes Unravel’s target and drug discovery platform, BioNAV™, which leverages a gene expression network AI model of human health to advance drugs for complex diseases in a target-agnostic manner, to identify small molecule modulators of endothelial activation.
  • Acute organ rejection is the leading cause of transplant failure, resulting in a growing interest in improving organ preservation and ex-vivo heart perfusion techniques increasing transport time while reducing the harsh impacts of ischemic injury.
  • VPS stands as a trailblazer in the field of organ preservation and transplant research, committed to pushing the boundaries of science to enhance transplant patient outcomes.

Cellusion Receives U.S. FDA Orphan Drug Designation for CLS001

Retrieved on: 
Friday, December 22, 2023
Research, Professional Services, Pharmaceutical, Optical, Start-Up, University, Education, Clinical Trials, Science, Biotechnology, FDA, Health, Food, Opacity, Freedom, Visual impairment, Regenerative medicine, Disease, ODD, Orphan, Human, Endothelium, Cell, Patient, Diagnosis, IPS, Paratriathlon, Cataract, Inc., Pharmaceutical industry

Ph.D., “Cellusion”), a deep tech start-up developing a novel cell therapy, announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to our regenerative medicine product “iPS cell-derived corneal endothelial cell substitute” (“CLS001”) for the treatment of bullous keratopathy.

Key Points: 
  • Ph.D., “Cellusion”), a deep tech start-up developing a novel cell therapy, announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to our regenerative medicine product “iPS cell-derived corneal endothelial cell substitute” (“CLS001”) for the treatment of bullous keratopathy.
  • FDA grants ODD if the drug meets specific criteria, the treatment, diagnosis, or prevention of rare diseases that affect less than 200,000 people in the United States.
  • The ODD qualifies sponsors for incentives, including tax credits for qualified clinical (in humans) testing, waiver of the prescription drug user fee and potential 7 years of market exclusivity after FDA approval.
  • With this designation, we will further accelerate the global development of CLS001 and aim to contribute to patients around the world who are waiting for the treatment.

Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023

Retrieved on: 
Friday, November 17, 2023
Kidney disease, Fistula, Patient, FIH, Endothelium, Infection, Dialysis, AVF, AVG, Pharmaceutical industry

The data was presented yesterday by Prof. Dr. Frans Moll at the 50th Annual VEITHsymposium in New York.

Key Points: 
  • The data was presented yesterday by Prof. Dr. Frans Moll at the 50th Annual VEITHsymposium in New York.
  • At 12 months, 100% secondary patency, 78% primary assisted patency and 0% infections were observed in data from 20 patients implanted with the aXess conduit.
  • This performance builds on the very encouraging 6-month data presented in April 2023 at the Vascular Access Society Congress in Porto, Portugal.
  • aXess is a restorative conduit which enables the creation of a new, long-term living vessel for hemodialysis vascular access.

Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University

Retrieved on: 
Wednesday, December 13, 2023
Licensing factor, Johns Hopkins University, FGF, HUVEC, Inhibitor, JHU, Itraconazole, Basal-cell carcinoma, Therapy, National Cancer Institute, VDAC1, INTI, Literature, Cell proliferation, Patient, BCC, EGF, Angiogenesis inhibitor, Prostate cancer, Endothelium, AMPK, VEGF, Neoplasm, System, License, Blood, Enzyme inhibitor, Cancer, ATP, Lung cancer, Growth, API, Metastasis, Invention, RNA, Patent, Pharmaceutical industry, Vaccine

TAMPA, Fla., Dec. 13, 2023 /PRNewswire/ -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) has entered into an exclusive, worldwide licensing agreement (the "License") with Johns Hopkins University (JHU) for their U.S Patent 8,980,930 (Canada Patent 2,572,223) "New Angiogenesis Inhibitors". Angiogenesis Inhibitors, as described by the National Cancer Institute, are unique cancer fighting agents as they block the growth of blood vessels that support tumor growth rather than blocking the growth of the tumor cells themselves. Inventors affiliated with JHU developed this patent, listing Itraconazole as an Active Pharmaceutical Ingredient (API) that has anti-angiogenic properties.

Key Points: 
  • TAMPA, Fla., Dec. 13, 2023 /PRNewswire/ -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) has entered into an exclusive, worldwide licensing agreement (the "License") with Johns Hopkins University (JHU) for their U.S Patent 8,980,930 (Canada Patent 2,572,223) "New Angiogenesis Inhibitors".
  • Inventors affiliated with JHU developed this patent, listing Itraconazole as an Active Pharmaceutical Ingredient (API) that has anti-angiogenic properties.
  • Inhibitor believes the License is a mutually beneficial agreement, yielding a modest annual royalty rate with milestone payments typical to such a license.
  • A total of 13 new 'surgically eligible' lesions across 8 of the 38 patients developed over the duration of the study.

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

Retrieved on: 
Thursday, November 16, 2023
Fibroblast, Parallel Walk Test, Endothelium, Therapy, Pathology, Scleroderma, Systemic scleroderma, CMMB, Axis, Risk, Pulmonary hypertension, Patient, Nature, American College of Rheumatology, Autoimmune disease, Orthostatic hypertension, American College, CCR3, Malignancy, CCL24, Sclerosis, Communication, Doctor of Philosophy, PAH, Skin, ACR, TEL, Pharmaceutical industry, Disease

TEL AVIV, Israel, Nov. 16, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported on its poster presentation at the American College of Rheumatology (ACR) Convergence 2023 conference. The study, which was conducted by Chemomab researchers working in collaboration with academic scientists, analyzed serum samples and clinical data from patients with systemic sclerosis (SSc) to assess the effect of the soluble protein CCL24 on the pathogenesis of SSc and its association with key aspects of SSc pathology. Chemomab's first-in-class monoclonal antibody, CM-101, is designed to neutralize CCL24 and normalize CCL24-driven fibro-inflammatory disease processes. CM-101 has been studied extensively in preclinical and patient models of SSc. Chemomab has an open IND in the U.S. for a Phase 2 trial of CM-101 in systemic sclerosis patients.

Key Points: 
  • Chemomab's first-in-class monoclonal antibody, CM-101, is designed to neutralize CCL24 and normalize CCL24-driven fibro-inflammatory disease processes.
  • Chemomab has an open IND in the U.S. for a Phase 2 trial of CM-101 in systemic sclerosis patients.
  • Systemic sclerosis is an autoimmune disease characterized by vascular injury and extensive tissue fibrosis of the skin and internal organs.
  • Using cell-based assays, the researchers showed that CCL24, alongside factors present in the SSc microenvironment, enhances the EndMT process.

Aurion Biotech Named “Regenerative Therapeutics Company Of The Year” By BioTech Breakthrough

Retrieved on: 
Wednesday, November 8, 2023
Health, Medical Devices, General Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Ophthalmology, Invention, MD, Corneal transplantation, Cell, Aqueous humour, Surgeon, Kyoto Prefectural University of Medicine, Endothelium, Therapy, Patient, Pharmaceutical industry

Aurion Biotech is a clinical stage company that is developing a novel cell therapy to treat patients with corneal endothelial disease, which affects more than 16 million people throughout the world.

Key Points: 
  • Aurion Biotech is a clinical stage company that is developing a novel cell therapy to treat patients with corneal endothelial disease, which affects more than 16 million people throughout the world.
  • Its cell therapy procedure is accessible for ophthalmologists, involving a single administration into the anterior chamber of the patient’s eye.
  • Leveraging the pioneering inventions of Professor Shigeru Kinoshita, MD, of Kyoto Prefecture University of Medicine, Aurion Biotech has acquired the technology for further development.
  • “We are honored to be named BioTech Breakthrough’s ‘Regenerative Therapeutics Company of the Year,’” said Greg Kunst, Aurion Biotech’s CEO.

Centricity Vision Announces Commercial Launch of ZEPTOLink IOL Positioning System at AAO Conference

Retrieved on: 
Wednesday, November 1, 2023
Phacoemulsification, CCC, Capsulorhexis, AAO, Single person, Suction, Foot, American Academy, Surgeon, American Academy of Ophthalmology, Cornea, Annual general meeting, Endothelium, Patient, PPC, Nursing, Veterinary medicine, MD, IOL

CARLSBAD, Calif., Nov. 1, 2023 /PRNewswire/ -- Centricity Vision Inc., a global ophthalmic technology company, announced today the commercial launch of its ZEPTOLink IOL Positioning System™ at the American Academy of Ophthalmology (AAO) Annual Meeting, November 3-6 in San Francisco. The new platform seamlessly integrates the clinically proven ZEPTO precision pulse capsulotomy technology with any phacoemulsification (phaco) system to streamline cataract surgery.

Key Points: 
  • New Platform Integrates With All Phacoemulsification Systems,
    CARLSBAD, Calif., Nov. 1, 2023 /PRNewswire/ -- Centricity Vision Inc. , a global ophthalmic technology company, announced today the commercial launch of its ZEPTOLink IOL Positioning System™ at the American Academy of Ophthalmology (AAO) Annual Meeting, November 3-6 in San Francisco.
  • ZEPTO is the first and only device that creates an instantaneous capsulotomy with consistent, 360-degree intraocular lens (IOL) overlap for optimal lens positioning and improved outcomes.
  • Now with the phaco integration, ZEPTOLink is the next evolution helping to drive the future of automated refractive cataract surgery.
  • Following AAO, Centricity Vision will upgrade existing users of the prior ZEPTO system to ZEPTOLink while also onboarding new accounts.

eGenesis Presents Preclinical Data Demonstrating Recipient Survival and Compatibility with Genetically Engineered Porcine Kidneys at 2023 IPITA-IXA-CTRMS Joint Conference

Retrieved on: 
Thursday, October 26, 2023
Massachusetts General Hospital, Survival, RNA, Antigen, CRISPR, Cell Transplantation, Organ dysfunction, Kidney, Cell, Pelvic floor dysfunction, Transgene, System, Organ transplantation, Risk, Congress, Complement, Gene, Endothelium, Transplant, Patient, NHP, Ischemia, Pharmaceutical industry, Dentistry, Vaccine, Nature

Two presentations will highlight data from the company’s landmark preclinical proof of concept study for kidney transplant recently published in Nature.

Key Points: 
  • Two presentations will highlight data from the company’s landmark preclinical proof of concept study for kidney transplant recently published in Nature.
  • A third presentation will share the results of a study evaluating pancreatic islets from genetically engineered porcine donors transplanted into a mouse model.
  • “We’re thrilled to share data highlighting our lead candidate for kidney transplant, EGEN-2784, as well as additional data supporting our genome engineering platform.
  • Humanized porcine donors were genetically engineered using the Yucatan miniature pig breed to carry 69 genomic edits through CRISPR/Cas 9 technology.